Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody.
about
Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potentialCancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers.A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinomaPlasmonic nanobubble-enhanced endosomal escape processes for selective and guided intracellular delivery of chemotherapy to drug-resistant cancer cells.Dynamic imaging of arginine-rich heart-targeted vehicles in a mouse model.Ultrasonic-activated micellar drug delivery for cancer treatment.Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer.Cooperative tumour cell membrane targeted phototherapy.Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.Nanostructured Surfaces to Target and Kill Circulating Tumor Cells While Repelling LeukocytesNanotargeted radionuclides for cancer nuclear imaging and internal radiotherapyLiposomal Cu-64 labeling method using bifunctional chelators: poly(ethylene glycol) spacer and chelator effects.Cholesterol derivatives based charged liposomes for doxorubicin delivery: preparation, in vitro and in vivo characterizationNANOMATERIALS FOR PROTEIN MEDIATED THERAPY AND DELIVERY.A novel small peptide as an epidermal growth factor receptor targeting ligand for nanodelivery in vitroA review on composite liposomal technologies for specialized drug delivery.Use of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy.Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment.A novel albumin nanocomplex containing both small interfering RNA and gold nanorods for synergetic anticancer therapy.Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers.In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel Heptameric ZEGFR domain.Construction of paclitaxel-loaded poly (2-hydroxyethyl methacrylate)-g-poly (lactide)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine copolymer nanoparticle delivery system and evaluation of its anticancer activity.Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer.Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor.Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in ratsChemotherapy targeting by DNA capture in viral protein particlesEnhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.Drug delivery to tumours: recent strategies.pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug deliverySynthesis and evaluation of a novel ligand for folate-mediated targeting liposomesTheranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives.pH-sensitive liposomes--principle and application in cancer therapy.Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.Targeted pharmaceutical nanocarriers for cancer therapy and imagingThe effect of particle design on cellular internalization pathways.Antibody-targeted liposomes in cancer therapy and imaging.Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice.Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice.Multifunctional and stimuli-sensitive pharmaceutical nanocarriers.Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody.
P2860
Q24657256-8EAD039F-E1ED-4EBA-B075-00B40622E3FAQ26830028-C911CA83-37A7-48C6-939C-0B424A2A83FFQ28487973-C85996F9-1DC8-47CC-BCB9-5F760D511BB5Q30458534-106159BF-F6AA-48BE-BBF9-886C7D0D8437Q30482759-27C8537C-EEC2-4E40-9E39-18F8C2B03F7EQ30490995-F2371138-C9C4-4736-846B-164B87FE42B8Q33681168-20E77FC9-06DA-405D-82AC-52DF79199389Q33827119-1493C479-DC46-45A7-81D8-C378D93F7FA2Q33943901-8BA4EF23-3659-4EB2-86CF-6644A3D80F42Q34069596-7838993E-F22D-4551-A72C-478D1484F80CQ34089324-CB3EFC0D-57CD-4D72-B1AC-8FC3A8B65EBAQ34144898-4EFDA474-7424-4EA4-B3B3-5B28D32C90BDQ34506844-1B3814AD-5826-4D0F-A276-5D63B3C84843Q34534023-9ADB3429-69C0-4A23-AF4A-2DE978C19E59Q34692050-A9C755B3-D5C9-4B20-82C9-37D7098389C9Q34730109-9E9AC3F8-26A7-4A2E-AC15-BA4D240C62E0Q35213029-C36CFED3-4B0C-4A5E-A4CD-FFE40094B413Q35609201-1AEB1BCB-28FF-4F40-8C63-EF09FDAE3008Q35619130-77BFB37A-4D52-44F4-A847-F4730916762CQ35772168-23BB8019-E09D-4670-A9B9-081F61C38E66Q35803276-FD0F73D9-3B47-4EB5-892F-CB5956ED58F2Q35822282-4206F16B-C2E2-4438-BF50-D0F4697E3578Q35837359-EFA67611-E440-46B3-9573-1F651E6D22BEQ36043818-EF3D2A91-70B6-40C5-B4BE-166F04F6992FQ36148614-6EFA9847-4ACC-40B0-A094-A1F0D50C7160Q36194380-2BC3B7A2-3863-4930-B555-9859A6B5D246Q36294611-44D3B9FE-77E3-4E78-9C38-A78A3FCEC187Q36301712-E8CC6486-8FCA-464E-A0A5-C309E45E4284Q36653608-30AE6FAC-994B-40E3-A4BF-E6BF7C236B7EQ36713632-5643B8B1-3E9D-4A96-AA05-74DA12F863F5Q36777292-FCF62458-7509-4FC3-8915-9186A50C708EQ36790100-64979399-4E25-41F6-AD7F-FFB159196824Q36791673-DA7CF45F-961A-4C2A-BE7A-9857A223DBE8Q36871933-D7129948-0661-4FE8-8A08-E282043B42A1Q36954579-2D4ABF50-840F-4BEE-A836-98FD9FD035E3Q37076367-23E0778E-75B5-46AD-BC79-E019BB42DDAAQ37117472-55C26E59-F5C7-4240-BA75-E9B540F00985Q37188366-AF2D3673-92B4-438C-825D-58008328F5F0Q37314628-E0502DF6-5A52-43EF-80B2-FABE69FDE77AQ37389006-F2CE91F7-D93A-4324-A270-C35A8847059F
P2860
Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Tumor-targeted liposomes: doxo ...... ied with anti-cancer antibody.
@en
type
label
Tumor-targeted liposomes: doxo ...... ied with anti-cancer antibody.
@en
prefLabel
Tumor-targeted liposomes: doxo ...... ied with anti-cancer antibody.
@en
P2093
P1476
Tumor-targeted liposomes: doxo ...... ied with anti-cancer antibody.
@en
P2093
Ananthsrinivas R Chakilam
Anatoly N Lukyanov
Tamer A Elbayoumi
Vladimir P Torchilin
P304
P356
10.1016/J.JCONREL.2004.08.007
P407
P577
2004-11-01T00:00:00Z